Billionaire Nominates BioMarin as Top Stock

Summary

Billionaire Paul Singer has listed BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of his top stock picks, indicating an average upside potential of 62.68%. Elliott Management holds $230.8 million in shares of the company. BioMarin focuses on treatments for rare diseases, with its product Voxzogo generating $214 million in Q1 2025 revenue, marking a 40% year-over-year increase. The company anticipates Voxzogo’s 2025 revenue to be between $900 million and $950 million. Oppenheimer reiterated an ‘Outperform’ rating for BMRN stock with a target price of $98.insidermonkey

Impact Analysis

The event is classified at the company level as it directly involves BioMarin Pharmaceutical Inc. and reflects investor sentiment due to Paul Singer’s endorsement and Elliott Management’s substantial shareholdings. First-order effects include increased investor interest and potential stock price appreciation, driven by positive revenue performance and strong future forecasts for Voxzogo. Second-order effects may involve broader attention to BioMarin’s market position in rare disease treatment, potentially influencing investor behavior in related sectors. Analyst ratings from Oppenheimer and others further support bullish sentiments, providing investment opportunities through potential stock appreciation based on growth expectations.insidermonkey+ 5